Longitudinal and age trends of metabolic syndrome and its risk factors: The Family Heart Study

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Kraja, Aldi T
    • Other Affiliation: Washington University School of Medicine
  • Borecki, Ingrid B
    • Other Affiliation: Washington University School of Medicine
  • North, Kari
    • Affiliation: Gillings School of Global Public Health, Department of Epidemiology
  • Tang, Weihong
    • Other Affiliation: University of Minnesota
  • Myers, Richard H
    • Other Affiliation: Boston University Medical Center
  • Hopkins, Paul N
    • Other Affiliation: University of Utah Health Sciences Center
  • Arnett, Donna
    • Other Affiliation: University of Alabama School of Public Health
  • Corbett, Jonathan
    • Other Affiliation: Washington University School of Medicine
  • Adelman, Avril
    • Other Affiliation: Washington University School of Medicine
  • Province, Michael A
    • Other Affiliation: Washington University School of Medicine
Abstract
  • Background We report longitudinal changes in the metabolic syndrome (MetS) in 2,458 participants from 480 families in the Family Heart Study. Participants were examined between 1994–96 (FHS-T1) and 2002–03 (FHS-T2), about 7.4 years apart. Additionally, the impact of medication on estimates of MetS prevalence, and associations of MetS with prevalent coronary heart disease (CHD) and type 2 diabetes (T2D) were studied. Methods Three definitions for MetS prevalence were considered. One represented the original (o) National Cholesterol Education Program (NCEP) MetS criteria. Two others considered the confounding of medications effects, respectively (m) lipid medications constituted a categorical diagnostic criterion for lipids variables, and (c) lipids and blood pressure variables were corrected with average clinical trials medications effects. Logistic regression of MetS on CHD and T2D, as well as the trend analysis of MetS by age, were performed. Results MetS increased from 17.1% in FHS-T1(o) to 28.8% in FHS-T2(o); from 19.7% in FHS-T1(m) to 42.5% in FHS-T2(m); and from 18.4% in FHS-T1(c) to 33.6% in FHS-T2(c). While we observed adverse changes in all risk factors, the greatest increase was for waist circumference (25%). The percentages of MetS were about 2 to almost 3 times higher in ages 50 years and older than in younger ages. The odds of having prevalent CHD were about 2.5 times higher in the subjects classified with MetS than without. Conclusion MetS percentages increased noticeably longitudinally and cross-sectionally with older age. These conclusions were reached with and without considering medication use, but correcting risk factors for medications use affects the MetS prevalence estimates. As found in other studies, MetS was associated with increased odds for prevalent CHD.
Date of publication
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
Rights holder
  • Aldi T Kraja et al.; licensee BioMed Central Ltd.
License
Journal title
  • Nutrition & Metabolism
Journal volume
  • 3
Journal issue
  • 1
Page start
  • 41
Language
  • English
Is the article or chapter peer-reviewed?
  • Yes
ISSN
  • 1743-7075
Bibliographic citation
  • Nutrition & Metabolism. 2006 Dec 05;3(1):41
Publisher
  • BioMed Central Ltd
Access right
  • Open Access
Date uploaded
  • September 5, 2012

Relations

Parents:

This work has no parents.

Items

Thumbnail Title Date Uploaded Visibility Actions
file details 1743-7075-3-41.pdf 2019-05-06 Public Download
file details 1743-7075-3-41.xml 2019-05-06 Public Download